SK Biopharm Q1 2026 Results: Revenue and Operating Profit Surge, Net Income Up 423.5% YoY
- Q1 2026 consolidated revenue KRW 227.8bn (YoY +57.8%), operating profit KRW 89.8bn (+249.7%), net income KRW 102.7bn (+423.5%).
- Sequential growth: revenue +17.2% QoQ, operating profit +94.0% QoQ, continuing improvement.
- Net income attributable to parent KRW 105.2bn, up 351.2% YoY, down 23.0% QoQ (base effect).
- These are preliminary figures, subject to change after external audit review.
ADVERTISEMENT (250px+)
KOSPI Filing Information
- Filing: Consolidated Financial Statements Basis Operating (Provisional) Results (Fair Disclosure)
- Company: SK Biopharmaceuticals (326030)
- Submission: SK Biopharmaceuticals Co., Ltd.
- Receipt: 05-07-2026
- Under KRX KOSPI Market Division